EGFR and melanoma: To date, some of the kinase inhibitors have been successfully developed into cancer therapy, for instance, Imatinib to BCR-ABL in chronic myelogenous leukemia [9], vemurafenib [10] to BRAFV600E in melanoma, cetuximab to ErbB1 in metastatic colon cancer [11], sunitinib to PDGFR, KIT and FLT3 in kidney cancer [12], and zactima to EGFR, VEGFR and RET in thyroid carcinoma [13].